Crystec are pleased to announce the opening of a new subsidiary, Nantong Crystec Pharmaceutical R&D Co. Ltd., and research facility, located at Haimen Science and Technology Park in Haimen City, Jiangsu Province, China.
Crystec’s new R&D centre has been established following an invitation to participate in the Yangtze Delta Advanced Drug Development platform jointly funded by the Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, and the Haimen government. The platform, which has received £550m equivalent in investment, is dedicated to accelerating pharmaceutical product innovation underpinned by advanced pharmaceutical excipients and drug delivery technologies. Crystec’s mSAS® technology will play a key role in enabling the development of new therapeutics, creation of value added medicines, and in simplification of formulations and manufacturing processes.
The new Haimen facility will support Crystec’s ongoing development strategy in China, working alongside Crystec’s existing China subsidiary, Tianjin Crystec Pharmaceutical Technology Ltd., and its UK headquarters in Bradford, UK, to expand and enhance product development services offered across the region and globally.
About CrystecPharma
CrystecPharma is a pharmaceutical crystal and particle engineering company, applying proprietary mSAS® supercritical fluid technology to improve the performance of medicines. The company has a strong research and development base, in both the UK and China. Crystec supports pharmaceutical companies to optimise the development of their own products, typically through improving bioavailability, stability or changing routes of administration. Use of the mSAS® platform can greatly shorten development times, generating high quality, readily-scalable products. The company also applies the strength of its technology to develop its own unique supergeneric products. Crystec is a young, dynamic company, with a passion for ensuring that strong science benefits human health.
